Johnson County Health Dept. responds to tuberculosis concerns
KANSAS CITY, Mo. — In response to a tuberculosis outbreak, the Johnson County Department of Health and Environment (JCDHE), the Wyandotte County Public Health Department, and the Kansas Department of Health and Environment have been working together since March 2024.
JCDHE confirmed Tuesday that all patients in Johnson County, comprising seven active cases and two latent cases, have completed treatment and are not infectious.
Kansas officials say risk is low after tuberculosis outbreak
More cases may be found among Johnson County residents as testing goes on. JCDHE said the risk to the general public remains low; however, it will monitor the situation closely and is taking all necessary steps to prevent a potential spread.
The response from Johnson County comes days after Kansas officials said there is a low risk to the public of contracting tuberculosis.
But according to online data, as of Friday, Jan. 24, there were 67 active cases of the disease. The breakdown includes 60 in Wyandotte County and seven in Johnson County.
TB is spread through the air from one person to another and is put into the air when a person with active TB disease of the lungs or throat coughs, speaks or sings.
Tuberculosis is not spread by touch, and you cannot get TB by walking past an infectious person.
Kansas news: Headlines from Wichita, Topeka and around the Sunflower State
Dr. Dana Hawkinson, Medical Director of Infection Prevention and Control with the University of Kansas Health System, also says the risk is low and treatment is available.
'Typically, it is four drugs for a few weeks, and then we go down to two drugs. Most of them are pills. People need to be treated for at least six months and sometimes longer,' Hawkinson shared.
Symptoms include a prolonged cough, which could include a bloody cough, night sweats and weight loss. These are symptoms that could persist for weeks or months. Hawkinson says it's difficult to tell if you may or may not be sick.
You can read more from the CDC about the Skin Test here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.
GMP TERBIUM-161 PRODUCT LAUNCHED BY TERTHERA BREDA, Netherlands, June 5, 2025 /PRNewswire/ -- TerThera B.V. has officially launched the world's first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide. Now, with the successful implementation of European Good Manufacturing Practices (GMP), TerThera's Terbium-161 meets the highest quality and safety standards required for clinical trials and patient care across Europe and beyond. This lowers regulatory barriers and accelerates the path to new therapies providing hospitals, clinicians, and researchers immediate access to this next-generation therapeutic radionuclide Terbium-161. A New Era in Cancer Treatment Terbium-161 NCA is a no-carrier-added, neutron-activated radionuclide uniquely suited for Radio Ligand Therapy (RLT). With an abundant emission of Auger electrons and high Linear Energy Transfer (LET), combined with similar chemical characteristics to well-known radiolanthanides, Tb-161 brings a high potential to decimate both primary tumors and (micro) metastases. When paired with proven targeting vectors like PSMA, SST, and FAPI analogues, Tb-161 demonstrates a bioequivalence while significantly increasing absorbed doses in all lesions, offering novel treatment options and strategies in cancer healthcare, improving the overall disease control and may even overcome radio-resistant disease. Global Vision, Local Innovation "This milestone is more than a regulatory achievement—it's a leap forward in our mission to bring Terbium-161 to patients worldwide," said Philippe van Overeem, CEO of TerThera. "GMP Terbium-161 is now a clinical reality, and this is just the beginning. We are actively constructing a large-scale production facility to meet the growing global demand and expand access to this promising radionuclide for optimized cancer treatments." With this launch, TerThera reaffirms its commitment to transforming the landscape of radiopharmaceuticals and leading the charge in precision oncology. About TerThera BV TerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT. support@ View original content: SOURCE TerThera Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Tuberculosis Therapeutics Market Opportunity, and Forecasts Report 2025-2030: Next-Gen Drug Development Demands, Cost Efficiency, Regulatory Agility, and Strategic Partnerships Influence on Growth
The Tuberculosis Therapeutics Market is driven by rising drug-resistant TB and persistent global demand. Opportunities include developing innovative, cost-effective TB drugs with shorter, more effective regimens. Companies can gain a competitive edge through strategic collaborations and navigating regulatory barriers. Tuberculosis Therapeutics Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Tuberculosis Therapeutics Market was valued at USD 2.18 Billion in 2024, and is expected to reach USD 2.94 Billion by 2030, rising at a CAGR of 5.05% Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development - particularly in second-line therapies - on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge. Key Market Drivers High Global Burden of TuberculosisThe global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial Market Challenges Inadequate Funding and Limited Commercial Incentives for Drug DevelopmentThe concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical Market Trends Shift Toward Shorter, More Effective Treatment RegimensThere is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.18 Billion Forecasted Market Value (USD) by 2030 $2.94 Billion Compound Annual Growth Rate 5.0% Regions Covered Global Report Scope Key Market Players AstraZeneca PLC Johnson & Johnson Services, Inc. Eli Lilly and Company Mylan Inc. Teva Pharmaceutical Industries Ltd Sanofi Novartis AG Sun Pharmaceutical Industries Ltd Pfizer Inc. Tuberculosis Therapeutics Market, By Disease Type: Active TB Latent TB Tuberculosis Therapeutics Market, By Therapy: First-Line Therapy Second-Line Therapy Tuberculosis Therapeutics Market, By Route of Administration: Oral Parenteral Others Tuberculosis Therapeutics Market, By Dosage Form: Tablets Capsules Injection Others Tuberculosis Therapeutics Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Tuberculosis Therapeutics Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Tuberculosis Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
6 days ago
- Yahoo
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US." Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. About ASP Isotopes Inc. ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company has isotope enrichment facilities in Pretoria, South Africa. For more information, please visit About Isotopia Molecular Imaging Ltd. Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy. This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. Contact: eshalom@ SOURCE Isotopia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
